Background-The prevalence of subclinical, cardiac troponin I (cTnI) elevation in stable patients undergoing elective percutaneous coronary intervention and its relationship to culprit lesion characteristics assessed by optical coherence tomography (OCT) are unknown. Methods and Results-We studied 206 native de novo culprit coronary lesions from 206 patients with stable angina pectoris who underwent OCT before elective percutaneous coronary intervention. Patients were divided into 2 groups according to the presence (cTnI group; n=47; 22.8%) or absence (non-cTnI group; n=159; 77.2%) of cTnI ≥0.03 ng/ mL at admission. The clinical and OCT findings were compared between these 2 groups. No significant difference was found in the clinical presentation between the groups except for the serum C-reactive protein levels and presence of multivessel disease. By OCT, cTnI elevation was associated with the presence of thin-cap fibroatheromas, a greater lipid arc, and a longer lipid length. In a multivariable analysis, the presence of positive C-reactive protein levels (odds ratio, 4.38; 95% confidence interval, 1.90-10.08; P=0.001) and OCT-derived thin-cap fibroatheromas (odds ratio, 2.89; 95% confidence interval, 1.22-6.86; P=0.016) were independent predictors of cTnI elevation. Periprocedural myocardial injury, defined as postpercutaneous coronary intervention peak cTnI levels >1.0 ng/mL (5× the upper reference limit), occurred more often in patients with cTnI elevation at admission (cTnI group: 41% versus non-cTnI group: 18%; P=0.001). Conclusions-The presence of subclinical cTnI elevation at admission was not uncommon and was associated with OCTderived unstable plaque morphology in patients undergoing elective percutaneous coronary intervention, and may help to identify patients with stable angina pectoris at high risk for periprocedural myocardial injury. (Circ Cardiovasc Interv.
C ardiac troponins as sensitive and specific biomarkers of myocardial necrosis have led to the redefinition of criteria for the diagnosis of myocardial infarction (MI). 1 Our understanding of minor troponin elevations or subclinical myocardial damage represented by detectable, highly sensitive troponin levels have been challenged, and existing paradigms have been revisited. In most patients with stable coronary artery disease, cardiac troponin I (cTnI) levels are below the limit of detection for conventional assays. However, when using high-sensitivity assays for cardiac troponins, recent studies have demonstrated the presence of detectable cardiac troponin levels in a large proportion of these patients. [2] [3] [4] Korosoglou et al 4 demonstrated recently that higher cardiac troponin T levels in patients with stable angina correlated with positively remodeled, noncalcified plaques on computed tomographic angiography. The Heart Outcomes Prevention Evaluation study 5 reported an association between high-sensitivity cTnI levels and the risk of cardiovascular events in a high-risk population. Moreover, Omland et al 3 reported a significant association between high-sensitivity cTnI levels and the incidence of acute MI. Evidence from an observational angioscopic study also showed that plaque rupture and thrombosis were present in ≈20% of patients with stable coronary heart disease. 6 Although the exact mechanism underlying subclinical cardiac troponin elevation in stable patients remains elusive, these studies favor the hypothesis that chronic but clinically silent microembolization from plaques with highrisk features of thrombogenesis may be a source of minor troponin elevation.
Intravascular optical coherence tomography (OCT), a highresolution imaging method for plaque characterization, [7] [8] [9] provides information on the microstructure of atherosclerotic plaques, including thin fibrous caps, lipid-rich plaques, and intracoronary thrombi, which may be responsible for plaque instability and subclinical myocardial damage with minor cTnI elevation. 10 We hypothesized that preprocedural OCT allows the detection of characteristic features of plaque and the evaluation of lesion-related factors associated with subclinical cTnI elevation in patients with stable angina pectoris (SAP). To test this hypothesis, we investigated the relationship between OCT-derived morphological features of culprit plaques in patients with a subclinical cTnI elevation undergoing elective stenting. We further assessed whether postpercutaneous coronary intervention (post-PCI) myocardial damage involving an elevation in troponin I to >5× the upper reference limit (URL) is associated with subclinical cTnI elevation observed at admission or OCT-derived culprit lesion plaque morphology in these patients.
Methods

Study Population
From January 2010 to December 2012, we prospectively enrolled 214 nonconsecutive patients with stable coronary artery disease who met the following criteria at Tsuchiura Kyodo General Hospital: age >20 years and detection of an identifiable, de novo single culprit lesion located at the proximal portion of a native coronary artery. Patients were also included when they had SAP, defined as no change in the frequency, duration, or intensity of anginal symptoms within 6 weeks before percutaneous coronary intervention (PCI). The target lesion was identified by a combination of coronary angiograms, ECG findings, angiographic lesion morphology, scintigraphic findings, perfusion cardiac magnetic resonance imaging, or fractional flow reserve measurements. Chest pain was classified into 4 classes of severity according to the criteria of the Canadian Cardiovascular Society. 11 All included patients had angina, documented myocardial ischemia, or both. The exclusion criteria were angiographically significant left main disease, previous coronary artery bypass surgery, renal insufficiency with a baseline serum creatinine level >1.5 mg/dL, acute coronary syndrome, cardiogenic shock, congestive heart failure, a totally occluded culprit lesion, and patients in whom culprit lesion identification was difficult. Patients treated with multivessel coronary intervention were excluded. All the patients underwent two-dimensional echocardiography before enrollment, and patients with an impaired systolic ejection fraction (<40%) or regional wall motion abnormalities in the myocardial territory supplied by the study vessel were also excluded from the study. In addition, patients with extremely tortuous vessels or heavy calcification and chronic total occlusion were excluded because of the anticipated difficulty in advancing the OCT catheter. Eight patients were excluded from the analysis because of failure of the imaging catheter in crossing the lesion or unsatisfactory OCT image quality. Thus, 206 SAP lesions from 206 patients were eventually analyzed in this study. All the patients had antiplatelet treatment with aspirin (200 mg/d) and clopidogrel (75 mg/d; loading dose, 300 mg) ≥24 hours before cardiac catheterization. The study protocol was approved by the institutional review board, and all the patients provided written informed consent before PCI.
Cardiac Catheterization
Each patient initially underwent standard selective coronary angiography and left ventriculography to delineate the coronary anatomy and assess left ventricle volumes and contractility using the radial artery with a 6-F system. All the patients received a bolus of heparin (5000 IU) before the procedure, and an additional bolus of 2000 IU was administered every hour if the procedure required >1 hour. An intracoronary bolus of nitroglycerin (0.2 mg) was administered at the start of the procedure and repeated every 30 minutes. PCI was performed using a 6-F guiding catheter via the radial approach in all the patients. Coronary stent implantation was performed with a balloon predilation in all the patients. The balloon/artery ratio for predilation was 0.9 to 1.0 in all the patients. To avoid aggressive stent expansion, stent size was guided using a combination of on-line quantitative coronary angiography and intravascular ultrasound, although the type of stent was selected at the operator's discretion. Successful PCI was defined as <25% residual stenosis as assessed by angiography. After achieving this end point, intravascular ultrasound was performed to confirm optimal stent deployment, and an additional PCI procedure was performed for suboptimal results.
Quantitative Coronary Angiographic Analysis
Quantitative coronary angiography was performed using the CMSMEDIS system (Medis Medical Imaging Systems, Inc, Leiden, The Netherlands). The minimum lumen diameter, reference diameter, and lesion length were measured in diastolic frames from orthogonal projections.
Biochemical Analysis
The Abbott Architect Troponin I assay (ARCHITECT i2000SR; Abbott Diagnostics, Abbott Park, IL, ) was performed (limit of detection, 0.01 ng/mL; coefficient of variation, <10% at 0.032 ng/mL,
WHAT IS KNOWN
• Population-based studies have demonstrated a strong association between high-sensitivity cardiac troponin (cTn) levels and all-cause and cardiovascular mortality that is independent of traditional cardiovascular risk factors.
• In stable patients with coronary artery disease, the prognostic value of minor troponin elevation has also been extensively debated, although pathophysiologic mechanisms of subclinical troponin leak have remained unclear.
• Intravascular optical coherence tomography, a highresolution imaging method for plaque characterization, provides information on the microstructure of atherosclerotic plaques, including thin fibrous caps, lipid-rich plaques, and intracoronary thrombi, which may be responsible for plaque instability and subclinical myocardial damage with minor cardiac troponin I elevation.
WHAT THE STUDY ADDS
• Our results indicate close relationship between subclinical cardiac troponin I elevation at admission and optical coherence tomography-derived culprit lesion instability, independently of conventional coronary risk factors in patients with stable angina pectoris undergoing elective stenting.
• Subclinical cardiac troponin I elevation at admission may help to identify high-risk patients of percutaneous coronary intervention-related myocardial injury in patients with stable angina pectoris. contemporary-sensitivity measures of third-generation cTnI assay). In this study, patients with SAP with cTnI levels ≥0.03 ng/mL on admission were defined as having subclinical cTnI elevation. The patients were divided into 2 groups based on the presence (cTnI group) or absence (non-cTnI group) of cTnI levels ≥0.03 ng/mL at admission, and the clinical presentations of the 2 groups were compared. Biochemical measurements were performed at admission, within 1 hour after PCI completion, 6 and 20 h after PCI, and thereafter if the parameters were still increasing. The maximum value was considered to represent the presence or absence of periprocedural myocardial injury (PPMI). The institutional 99th percentile URL by this assay for diagnosing acute coronary syndrome is 0.20 ng/mL, and PPMI was defined as a cTnI level >1.0 ng/mL (0.20 ng/mL: institutional URL×5) based on the third universal definition of MI. 1 The serum C-reactive protein (CRP) concentration was measured using a high-sensitive assay kit (N-Assay LA CRP-T, Nittobo, Tokyo, Japan). Positive CRP values of the assay were defined as >0.05 mg/dL (limit of detection, 0.01 mg/dL; coefficient of variation, 2.5% at 0.10 mg/dL) at admission.
OCT Image Acquisition and Analysis
OCT imaging of culprit lesions was acquired before PCI using either the commercially available time-domain M2/M3 Cardiology Imaging System (St. Jude Medical Inc, LightLab Imaging Inc, Westford, MA) or frequency-domain OCT C7 system and Dragon Fly catheter (St. Jude Medical Inc). Patients requiring predilatation before OCT imaging were excluded. In the M2/M3 system, an occlusion balloon (Helios; LightLab Imaging Inc) was inflated proximal to the lesion at 0.4 to 0.5 atm during image acquisition. The entire lesion length was imaged using an automated pullback system, distally to proximally, at a rate of 1.0 mm/s, and saline was continuously infused from the tip of the occlusion balloon. In the C7 system, a 2.7-F OCT imaging catheter was advanced distal to the lesion. Automated pullback was performed at 20 mm/s, whereas blood was displaced by a short injection of contrast media or dextran through the guiding catheter. The images were digitally stored for off-line analysis. All the OCT images were analyzed using proprietary software (LightLab Imaging Inc) at the Tsuchiura Kyodo Hospital OCT Core Laboratory by 2 experienced investigators who were blinded to the angiographic data and clinical presentations using previously validated criteria for OCT plaque characterization. 10, 12, 13 When discordance was evident between the observers, a consensus reading was obtained from a third investigator. A 30-mm segment of the culprit lesion (≈15-mm proximal and 15-mm distal to the culprit most stenotic lesion site) was examined in all the culprit vessels. The image location of all the target sites was determined using a fluoroscopic reference and landmarks, including the aorto-ostial junction, proximal and distal side branches, and calcification sites, in combination with the constant pullback speed of the imaging wire and OCT findings for each plaque. Contiguous crosssections were analyzed at 0.5-mm intervals. Plaques were classified into 2 categories: fibrous (homogeneous and high-backscattering region) or lipid (low-signal region with a diffuse border). 10, 13, 14 When lipid was present in >90° in any of the cross-sectional images within the plaque, it was considered a lipid-rich plaque. 8, 10, 15, 16 For each plaque, the cross-sectional image with the highest number of lipid quadrants was used for further analysis. Lipid length was determined for lipid-rich plaques using a longitudinal view. For all the images with a lipid core, the overlying fibrous cap thickness was measured at its thinnest part. The average of 3 measurements was taken for each image. For each culprit plaque, the minimum value was used for subsequent analysis. A thin-cap fibroatheroma (TCFA) was defined as a lipid-rich plaque with a fibrous cap thickness <80 μm. 17 The presence of fibrous cap disruption and intracoronary thrombi was also noted. Fibrous cap disruption was identified by the presence of fibrous cap discontinuity and cavity formation in the plaque, and a plaque with fibrous cap disruption was termed a ruptured plaque. In the ruptured plaque, a residual fibrous cap was identified as a flap between the lumen and cavity of the plaque, and its thickness was measured at the thinnest part. Intracoronary thrombi were identified by mass images (diameter >100 μm) protruding into the lumen. Macrophage accumulation was defined as signal-rich, distinct, or confluent punctuate regions that exceeded the intensity of the background speckle noise ( Figure 1F ). [18] [19] [20] Microchannels were defined as signal-poor voids that were sharply delineated in multiple contiguous frames ( Figure 1D ). 14, 18, 21 Cholesterol crystals were defined as linear, highly backscattering structures within the plaque ( Figure 1E ). 18 Macrophage accumulation, cholesterol crystals, microchannels, plaque disruption, and thrombi were recorded only for their presence. Interobserver variability and intraobserver variability were assessed by 2 independent observers and by the same observer at 2 separate time points, respectively.
Statistical Analysis
Data analysis was performed using SPSS22.0 (SPSS Inc, Chicago, IL). The normality of the data was verified using the Kolmogorov-Smirnov test. Categorical data were expressed as absolute frequencies and percentages, and were compared using χ 2 or Fisher exact test, as appropriate. Continuous variables were expressed as mean±SD for normally distributed variables and as median values (25th-75th percentiles) for non-normally distributed variables, and compared using Student t test and the Mann-Whitney U test, respectively. Interobserver agreement and intraobserver agreement in the OCT findings were assessed by the κ statistic of concordance. The relationship between subclinical cTnI elevation (dependent variable), clinical and angiographic characteristics, OCT findings, and other potential confounders was assessed using a multivariable logistic regression analysis (stepwise forward method) to determine whether the OCT findings remained associated with subclinical cTnI elevation. The relationship between PPMI and other variables was also evaluated to determine the predictive factors for post-PCI myocardial injury. Associated variables on univariable analyses (P<0.10) were included in the model. Considering the associations among factors, such as lipid-rich plaques, lipid quadrants, TCFAs, and fibrous cap thickness obtained from OCT findings, the presence of TCFAs was included as an OCT-derived factor in a multivariable analysis. An exploratory analysis was performed when parametric comparison is needed between the patients with cTnI values <0.03 ng/mL (undetected) and those with cTnI >0.03 ng/mL. For statistical reason, the values <0.03 ng/mL were defined as 0.02 ng/mL in the specific analyses. A P-value <0.05 was deemed to indicate statistical significance.
Results
Of the 206 patients who underwent successful OCT examinations, 3 had distal embolization exhibiting a final thrombolysis in MI flow grade <2 at the time of PCI completion. Sidebranch occlusion (>2 mm in diameter) was detected in 5 patients. These 8 patients were excluded from the analysis of predictors of PPMI. Thus, we evaluated 206 lesions from 206 patients with SAP to investigate the association between subclinical cTnI elevation and the clinical and OCT findings. We further evaluated 198 lesions from 198 patients with SAP who were successfully treated with elective stenting to investigate the relationship between PPMI and the clinical, procedural, and OCT findings.
Patient Characteristics, and Angiographic and Procedural Results
The baseline patient characteristics and angiographic findings of this study are summarized in Table 1 . Fortyseven patients (22.8%) showed a subclinical cTnI elevation at admission. No significant difference was found in the clinical presentations between the 2 groups except for serum CRP levels and the presence of multivessel disease, although there are some nonsignificant differences, such as in the frequency of female sex, smoking status, and the history of previous PCI. In 206 patients, 198 lesions from 198 patients were successfully treated with stent implantation: 124 lesions with everolimus-eluting stents, 60 with zotarolimus-eluting stents, 17 with biolimus-eluting stents, and 23 with bare-metal stents. Bare metal stents were used in 23 lesions.
OCT Findings
No serious complication was observed during OCT, and no patient presented with worsening of coronary flow or symptoms after OCT. The OCT findings are summarized in Table 2 .
Predictors of Subclinical cTnI Elevation
The results of univariable and multivariable logistic regression analyses for subclinical cTnI elevation at admission 
Predictors of PPMI
The baseline characteristics and angiographic findings, including procedural variables, and OCT findings in patients with or without PPMI are summarized in Tables 4 and 5 . Forty-six patients (23.2%) showed PPMI. No significant difference was noted in the baseline clinical characteristics and procedural variables except for the presence of subclinical cTnI elevation, lesion length by quantitative coronary angiography, and stented length between patients with and without PPMI. In the multivariable analysis, stented length, OCT-derived TCFA, and subclinical cTnI elevation were independent predictors of PPMI (Table 6 ). When considering only preprocedural variables, including OCT findings for predicting PPMI, PPMI occurred more frequently in patients with subclinical cTnI elevation or OCT-derived TCFAs (Figure 2 ). 
Interobserver Agreement and Intraobserver Agreement in the OCT Findings
The interobserver κ coefficients for thrombi, plaque rupture, the presence of TCFAs, macrophage accumulation, cholesterol crystals, and microchannels were 0.93, 0.91, 0.86, 0.81, 0.76, and 0.82, respectively. The intraobserver κ coefficients for thrombi, plaque rupture, the presence of TCFAs, macrophage accumulation, cholesterol crystals, and microchannels were 0.95, 0.92, 0.90, 0.86, and 0.86, respectively.
Discussion
In this study, the prevalence of subclinical cTnI elevation was 22.8% and a significant relationship was identified between the presence of subclinical cTnI elevation at admission and unstable OCT-derived, culprit lesion plaque characteristics in patients with SAP undergoing elective stenting. Our results also demonstrate that a subclinical elevation in cTnI at admission was significantly associated not with culprit lesion angiographic stenosis severity but with atherosclerotic burden defined as having multivessel coronary disease. Our data showed that the presence of positive CRP levels were also significantly associated with subclinical cTnI elevation. We further observed that PPMI with cTnI elevation exceeding 5×URL occurred more frequently in patients with subclinical cTnI elevation at admission. Recent studies have reported that low circulating levels of cardiac troponin are detectable in one fifth of patients with stable coronary artery disease and preserved left ventricle function. 2, 3, 5 These studies have also demonstrated that multiple conventional risk factors are associated with higher troponin concentrations and that low circulating levels of troponin have a graded relationship with the incidence of cardiovascular death and heart failure in such patients. 22 All data are presented as the number (n [%]), mean±SD, or median (interquartile range). ACC indicates American College of Cardiology; AHA, American Heart Association; CCS, Canadian Cardiovascular Society; CRP, C-reactive protein; CRP positive, CRP>0.05 mg/dL; CTFC, corrected TIMI frame count; cTnI, cardiac troponin I; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, highdensity lipoprotein; LAD, left anterior descending; LCX, left circumflex; LDL, low-density lipoprotein; MI, myocardial infarction; MLD, minimal lumen diameter; PCI, percutaneous coronary intervention; RCA, right coronary artery; RD, reference diameter; TIMI, thrombolysis in myocardial infarction; URL, upper reference limit; and WBC, white blood cell. Total (n=198) cTnI After PCI >5×URL (n=46) cTnI After PCI ≤5×URL (n=152) P Value may occur in the absence of flow-limiting stenosis. Thus, the dissociation between troponin leakage and lumen narrowing or symptom severity as observed in our study is not surprising. Asymptomatic, nonflow-limiting plaque rupture with subsequent microembolization of atherothrombotic debris into the coronary artery has been recognized. 6, 24, 25 However, the frequency in patients with SAP and the clinical relevance to cardiac marker elevation remain elusive. Ours and other studies suggest that silent, minor plaque disruption, and microembolization are major factors of plaque progression and support the present hypothesis. 4, 6 However, biomarker elevation, particularly a small or mild increase, may be a risk marker for disease burden or lesion complexity and not a causal mediator of late mortality. 2, 26 Seifarth et al 27 reported association between coronary artery plaque burden assessed by coronary computed tomography and CRP and troponin concentration. Korosoglou et al 4 reported that high-sensitivity cardiac troponin is associated with quantitative characteristics of coronary plaque composition using computed tomography in patients with SAP. Our results are in line with these findings and showed the significant association between low levels of CRP elevation and subclinical TnI elevation in stable patients. This study extends these previous findings and showed for the first time that the significant association between subclinical cTnI elevation and OCT-derived culprit lesion instability, and between low levels of CRP elevation and cTnI elevation in patients undergoing elective PCI.
Little disagreement exists about the prognostic consequences of large periprocedural myocardial damage, but the clinical significance of smaller enzymatic myocardial injury in patients with otherwise successful PCI continues to be controversial. In this study, PPMI was defined as a peak cTnI level >1.0 ng/mL after PCI (0.20 ng/mL: institutional URL×5), which is required to diagnose Type 4a MI. 1 Our results, demonstrating that patients with SAP undergoing elective PCI with subclinical cTnI elevation at admission carry greater susceptibility to PPMI and a worse prognosis, were in line with the study by Prasad et al. 22 Biomarker elevation after elective PCI may highlight patients with more unstable plaques who are candidates for recurrent cardiovascular events. 16, 26 This hypothesis seems to be consistent with the study of Ellis et al. 28 They identified an early, high-risk period of events for patients with creatine kinase-myocardial band elevation after PCI, in addition to a late mortality risk beyond 12 months. Biomarker elevation, particularly a small or mild increase after PCI, may also be a risk marker for disease burden or lesion complexity and not a causal mediator of late cardiac events. For treating high-risk lesions or SAP patients with TCFA and subclinical cTnI elevation, drug administration or therapies before PCI, including glycoprotein IIb/IIIa inhibitors, statins, and dual antiplatelet therapy, should be considered. Distal or proximal protection devices might be effective in reducing distal embolization, or deferral of PCI and continued optimal medical therapy might be an alternative therapeutic option for these high-risk patients with PPMI. The assessment of low-level, chronic myocardial necrosis represented by a subclinical elevation in troponin may represent a new means by which clinicians can stratify risk among patients for stable coronary artery disease scheduled for elective PCI. Furthermore, preventing troponin release or a therapeutic strategy to reduce chronic subclinical troponin elevation may become an additional, new target for the treatment of patients with SAP undergoing elective stenting.
Limitations
Several limitations in this study should be noted. Our study consisted of a relatively small number of subjects who met the eligibility criteria at a single center. Excluding patients or lesions, including patients with significant left main coronary artery disease, renal impairment, or cardiogenic shock, may have resulted in a selection bias. Furthermore, most of the patients were on various medications at the time of study enrollment. In this study, only one measurement of cTnI at admission was used for the analysis. However, sequential or repeated measurements are needed because it is currently unknown for how long and at what frequency the episodes of increased cTnI levels occur in the present patient population. Currently, no imaging device or in vivo technique can discriminate lipid-rich plaques, TCFAs, or erosions with a history of rupture healing from never-ruptured lipid-rich TCFAs or erosions, and all these high-risk plaques of thrombogenesis may be observed as TCFAs by OCT. The cut-off value selected for subclinical cTnI elevation (0.03 ng/mL) was determined based on the guideline requisite of a coefficient of variation <10% at 0.032 ng/mL for the contemporary-sensitivity third-generation cTnI measurement method used in this study. The cut-off value by the recently introduced newer generation, high-sensitivity troponin assay or the present threshold merit prospective validation in larger patient cohorts in future studies.
Conclusions
Subclinical cTnI elevation was associated with unstable, OCT-derived plaque morphology in patients undergoing elective PCI and may help to identify SAP patients at high risk for PPMI.
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Figure 2.
Rates of periprocedural myocardial injury (PPMI) in patients with or without subclinical cardiac troponin I elevation at admission and with or without thin-cap fibroatheromas (TCFAs). Left, PPMI rates associated with or without cardiac troponin I (cTnI) at admission ≥0.03 ng/mL. Middle, PPMI rates associated with or without TCFAs. Right, PPMI rates associated with cTnI ≥0.03 ng/mL at admission and a TCFA vs without. CI indicates confidence interval.
